Trailing-twelve-month (TTM) revenue is $20.84 Billion with a year-over-year growth of (2.56%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q4 FY2025Period ended 2025-09-30 | $5,890,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-25 |
| Q1 FY2026Period ended 2025-12-31 | $5,252,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-09 |
| Q2 FY2026Period ended 2026-03-31 | $4,714,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q3 FY2026Period ended 2026-06-30 | $4,983,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $20,839,000,000 |
Current P/S: $49,004,789,000 market capitalization ÷ $20,839,000,000 TTM revenue = 2.35x.
Market capitalization source: FMP quote. Quote observed 2026-09-11T20:00:02.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q3 FY2026 (2026-06-30): $4.98B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-11T23:00:52.209Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-10.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-09-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-09-30 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-09-30 · USD | FY20212021-09-30 · USD | FY20222022-09-30 · USD | FY20232023-09-30 · USD | FY20242024-09-30 · USD | FY20252025-09-30 · USD |
|---|---|---|---|---|---|---|
| Interventional | $3.8B | $4.2B | $4.5B | $4.7B | $5.0B | $5.2B |
| Life Sciences | $4.7B | $6.5B | $5.6B |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-09-30 · USD | FY20212021-09-30 · USD | FY20222022-09-30 · USD | FY20232023-09-30 · USD | FY20242024-09-30 · USD | FY20252025-09-30 · USD |
|---|---|---|---|---|---|---|
| Asia | $2.6B | $3.3B | $3.0B | $2.9B | $2.9B | $3.1B |
| Europe | $3.5B | $4.8B | $4.0B | $4.2B |
$20.84B
$20.84 Billion
(2.56%)
vs. $21.39B a year ago (TTM)
+1.22%
5 Year compound annual growth rate
1 Year
(2.56%)
3 Year
+3.04%
5 Year
+1.22%
10 Year
+5.41%
15 Year
+7.10%
20 Year
+6.74%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $21.84B | +$1.66B | +8.23% |
| 2024 | $20.18B | +$806.00M | +4.16% |
| 2023 | $19.37B | +$502.00M | +2.66% |
| 2022 | $18.87B | ($261.00M) | (1.36%) |
| 2021 | $19.13B | +$3.06B | +19.02% |
| 2020 |
TTM Growth
(2.56%)
3-Year CAGR
+3.04%
5-Year CAGR
+1.22%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-11T23:00:52.209Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-10.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $5.2B |
| $5.2B |
| Medical | $8.7B | $9.5B | $8.8B | $9.5B | $10.1B | $11.5B |
|---|
| $4.7B |
| Others Country | $1.4B | $1.3B | $1.1B | $1.1B | $1.2B | $1.2B |
|---|
| UNITED STATES | $9.7B | $11.0B | $10.7B | $11.1B | $11.7B | $12.8B |
|---|
| $16.07B |
| ($1.22B) |
| (7.03%) |
| 2019 | $17.29B | +$1.31B | +8.18% |
| 2018 | $15.98B | +$3.89B | +32.17% |
| 2017 | $12.09B | ($390.00M) | (3.12%) |
| 2016 | $12.48B | +$2.20B | +21.41% |
